QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:BWAY

BrainsWay (BWAY) Stock Price, News & Analysis

$6.34
+0.02 (+0.32%)
(As of 02/22/2024 ET)
Today's Range
$6.12
$6.67
50-Day Range
$5.78
$7.46
52-Week Range
$1.38
$7.61
Volume
94,878 shs
Average Volume
152,013 shs
Market Capitalization
$105.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

BrainsWay MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
10.4% Upside
$7.00 Price Target
Short Interest
Healthy
0.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of BrainsWay in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.22) to ($0.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

624th out of 934 stocks

Surgical & Medical Instruments Industry

68th out of 91 stocks


BWAY stock logo

About BrainsWay Stock (NASDAQ:BWAY)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BWAY Stock Price History

BWAY Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Best Momentum Stocks to Buy for January 2nd
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
BrainsWay: Positive Cash Flow And Continued Growth
How Much Do Broadway Actors Make?
5 Analysts Have This to Say About BrainsWay
Preview: BrainsWay's Earnings
See More Headlines
Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
2/22/2024
Next Earnings (Confirmed)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BWAY
Fax
N/A
Employees
134
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$12.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+10.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-13,350,000.00
Pretax Margin
-27.20%

Debt

Sales & Book Value

Annual Sales
$28.79 million
Book Value
$2.75 per share

Miscellaneous

Free Float
13,463,000
Market Cap
$105.38 million
Optionable
Not Optionable
Beta
1.23
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Hadar Levy (Age 50)
    Chief Executive Officer
    Comp: $470.16k
  • Mr. Avner Hagai (Age 68)
    Founder & Director
    Comp: $47.37k
  • Prof. Abraham Zangen (Age 54)
    Co-Founder, Member of Scientific Advisory Board & Director
    Comp: $77.2k
  • Mr. Christopher J. Boyer Ph.D. (Age 46)
    Vice President of Global Marketing
    Comp: $337.95k
  • Dr. Yiftach Roth Ph.D. (Age 53)
    Founder & Chief Scientific Officer
    Comp: $108k
  • Mr. Ido Marom
    Chief Financial Officer
  • Mr. Menachem C. Klein Esq.
    VP, General Counsel & Corporate Secretary
  • Dr. Aron Tendler
    Chief Medical Officer














BWAY Stock Analysis - Frequently Asked Questions

Should I buy or sell BrainsWay stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BWAY shares.
View BWAY analyst ratings
or view top-rated stocks.

What is BrainsWay's stock price target for 2024?

3 equities research analysts have issued 12 month target prices for BrainsWay's stock. Their BWAY share price targets range from $3.00 to $12.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 10.4% from the stock's current price.
View analysts price targets for BWAY
or view top-rated stocks among Wall Street analysts.

How have BWAY shares performed in 2024?

BrainsWay's stock was trading at $6.48 at the beginning of 2024. Since then, BWAY stock has decreased by 2.2% and is now trading at $6.34.
View the best growth stocks for 2024 here
.

Are investors shorting BrainsWay?

BrainsWay saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 136,300 shares, a drop of 24.7% from the January 15th total of 180,900 shares. Based on an average daily volume of 175,100 shares, the days-to-cover ratio is presently 0.8 days.
View BrainsWay's Short Interest
.

When is BrainsWay's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our BWAY earnings forecast
.

How can I listen to BrainsWay's earnings call?

BrainsWay will be holding an earnings conference call on Wednesday, March 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were BrainsWay's earnings last quarter?

BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.06. The company had revenue of $8.30 million for the quarter, compared to analyst estimates of $7.70 million. BrainsWay had a negative net margin of 28.45% and a negative trailing twelve-month return on equity of 19.17%. During the same quarter in the previous year, the business posted ($0.15) earnings per share.

What other stocks do shareholders of BrainsWay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

When did BrainsWay IPO?

(BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO.

Who are BrainsWay's major shareholders?

BrainsWay's stock is owned by many different institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (6.25%), Worth Venture Partners LLC (1.56%), Essex Investment Management Co. LLC (1.42%), Legato Capital Management LLC (0.50%), Psagot Value Holdings Ltd. Israel (0.32%) and Barclays PLC (0.23%).

How do I buy shares of BrainsWay?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BWAY) was last updated on 2/22/2024 by MarketBeat.com Staff